US 11,744,828 B2
Regimens of tafenoquine for prevention of malaria in malaria-naïve subjects
Geoffrey S. Dow, Washington, DC (US); Bryan L. Smith, Chevy Chase, MD (US); John P. Jones, Richmond, VA (US); Moshe Shmuklarsky, Bethesda, MD (US); and Budda Balasubrahmanyam, Richmond, VA (US)
Assigned to 60 Degrees Pharmaceuticals LLC, Washington, DC (US); and The Government Of The United States As Represented By The Secretary Of The Army, Fort Detrick, MD (US)
Filed by 60 Degrees Pharmaceuticals LLC, Washington, DC (US)
Filed on Jan. 11, 2021, as Appl. No. 17/145,530.
Application 17/145,530 is a continuation of application No. 16/504,533, filed on Jul. 8, 2019, granted, now 10,888,558.
Application 16/504,533 is a continuation of application No. 15/532,280, granted, now 10,342,791, previously published as PCT/US2015/063425, filed on Dec. 2, 2015.
Claims priority of provisional application 62/086,355, filed on Dec. 2, 2014.
Prior Publication US 2021/0267962 A1, Sep. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4706 (2006.01); C07D 215/40 (2006.01); A61P 33/06 (2006.01)
CPC A61K 31/4706 (2013.01) [A61P 33/06 (2018.01); C07D 215/40 (2013.01); Y02A 50/30 (2018.01)] 10 Claims
 
1. A method of prevention of symptomatic P. falciparum malaria in a human subject, comprising:
a) administering to the human subject three loading doses of tafenoquine, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine, wherein each loading dose comprises about 200 mg of tafenoquine and is administered once a day for three days prior to potential exposure of the subject to P. falciparum;
b) administering to the human subject a maintenance dose of tafenoquine, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine once per week during potential exposure of the subject to P. falciparum, wherein each maintenance dose comprises about 200 mg of tafenoquine; and
c) administering to the human subject a post-exposure dose of tafenoquine, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine once seven days after the last maintenance dose, wherein said post-exposure dose comprises about 200 mg of tafenoquine;
wherein the first maintenance dose is administered seven days after the third loading dose;
wherein the administering of said a), b), and/or c) is with food; and
wherein the human subject is malaria-naïve and does not have a Glucose-6-phosphate dehydrogenase (G6PD) deficiency.